Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up – Time to Buy?

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) gapped up before the market opened on Wednesday . The stock had previously closed at $40.99, but opened at $43.94. Zealand Pharma A/S shares last traded at $43.94, with a volume of 368 shares.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. BTIG Research raised Zealand Pharma A/S to a “strong-buy” rating in a report on Friday, November 28th. William Blair restated a “market perform” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a research note on Tuesday, December 16th. Finally, BNP Paribas Exane downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. Three investment analysts have rated the stock with a Strong Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy”.

Zealand Pharma A/S Stock Performance

The company has a debt-to-equity ratio of 0.02, a current ratio of 23.57 and a quick ratio of 23.57. The company has a market capitalization of $3.16 billion, a price-to-earnings ratio of 3.25 and a beta of 0.75. The business’s 50 day simple moving average is $56.48 and its 200 day simple moving average is $68.15.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last announced its earnings results on Thursday, February 19th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($1.34) by $0.53. Zealand Pharma A/S had a net margin of 70.06% and a return on equity of 48.10%. The business had revenue of $10.79 million during the quarter, compared to the consensus estimate of $19.69 million. Research analysts anticipate that Zealand Pharma A/S will post -2.19 EPS for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.